LD-2 disclosure · 4th Quarter - Report
HOSPIRA, INC.
Client
- Name
- HOSPIRA, INC.
- Description
- Device and drug manufacturer
- Location
- Illinois · United States of America
Registrant
- Description
- Law Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesBudget/Appropriations
S. 1413: FDA User Fee Protection Act; H.R. 2725: FDA Safety Over Sequestration Act of 2013; PL 113-67: The Bipartisan Budget Act of 2013; H.R. 3547: 2014 Consolidated Appropriations Act PHA; PL113-54: Drug Quality and Security Act; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
LobbyistsHENRY W MENN iii · LISA LAYMAN · CHRISTOPHER BOWLIN
TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office
Pharmacy
Issues relating to generic drug labeling; S. 959: The Pharmaceutical Quality, Security and Accountability Act; H.R. 3204: The Compounding Clarity Act
LobbyistsHENRY W MENN iii · LISA LAYMAN · CHRISTOPHER BOWLIN
TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office
Health Issues
Issues relating to drug and nutrient shortages; P.L. 111-148: Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 232: Medical Device Access and Innovation Protection Act
LobbyistsHENRY W MENN iii · LISA LAYMAN · CHRISTOPHER BOWLIN